This came despite GSK posting a 5% rise in core operating profits, excluding exceptional items and currency movements, to £3.08 billion for the third quarter, against the £2.93 billion expected in the market, as sales on a constant currency basis lifted 5%.
To provide well-rounded coverage and a breadth of insight across various events, we rely on contributions from several staff writers, each bringing their own area of expertise to our publication.
